Catheter Precision, Inc. Signs Material Definitive Agreement

TL;DR

CPCI inks new material deal, details TBD.

AI Summary

On August 30, 2024, Catheter Precision, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company, formerly known as Ra Medical Systems, Inc., is based in Fort Mill, SC, and operates in the surgical and medical instruments sector.

Why It Matters

This filing indicates a significant new agreement for Catheter Precision, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing reports a material definitive agreement, but the lack of specific details about the agreement introduces uncertainty.

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• Ra Medical Systems, Inc. (company) — Former company name
• August 30, 2024 (date) — Date of earliest event reported
• Fort Mill, SC (location) — Principal executive offices location

FAQ

Key Financial Figures

• $1.00 — s, priced at a public offering price of $1.00 per unit, with each unit consisting of
• $0.9999 — s, priced at a public offering price of $0.9999 per unit, with each unit consisting of
• $0.0001 — of common stock at an exercise price of $0.0001 per share that has no expiration date (
• $2.6 million — able by the Company, were approximately $2.6 million. Each Series H Warrant is exercisable
• $1 — at a price per share of common stock of $1.00, each Series I Warrant is exercisabl

Filing Documents

• rmed_8k.htm (8-K) — 42KB
• rmed_ex11.htm (EX-1.1) — 240KB
• rmed_ex41.htm (EX-4.1) — 105KB
• rmed_ex42.htm (EX-4.2) — 101KB
• rmed_ex43.htm (EX-4.3) — 93KB
• rmed_ex44.htm (EX-4.4) — 96KB
• rmed_ex45.htm (EX-4.5) — 101KB
• rmed_ex991.htm (EX-99.1) — 8KB
• rmed_ex992.htm (EX-99.2) — 5KB
• 0001654954-24-011589.txt ( ) — 1109KB
• rmed-20240830.xsd (EX-101.SCH) — 6KB
• rmed-20240830_lab.xml (EX-101.LAB) — 14KB
• rmed-20240830_cal.xml (EX-101.CAL) — 1KB
• rmed-20240830_pre.xml (EX-101.PRE) — 9KB
• rmed-20240830_def.xml (EX-101.DEF) — 2KB
• rmed_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On August 30, 2024, Catheter Precision, Inc., a Delaware corporation (the "Company"), entered into an Underwriting Agreement (the "Underwriting Agreement") with Ladenburg Thalmann & Co. Inc., as representative of the underwriters named in the Underwriting Agreement (the "Underwriters"), pursuant to which the Company issued and sold, in a firm commitment underwritten public offering by the Company (the "Public Offering"), (i) 805,900 common stock units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the five year anniversary of the date of issuance (a "Series J Warrant"), and (ii) 2,773,000 pre-funded units, priced at a public offering price of $0.9999 per unit, with each unit consisting of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001 per share that has no expiration date (a "Pre-Funded Warrant" and together with the Series H Warrants, Series I Warrants and Series J Warrants, the "Warrants"), one Series H Warrant, one Series I Warrant and one Series J Warrant. The Public Offering closed on September 3, 2024. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters a 45-day option (the "Overallotment Option") to purchase up to (i) 468,041 additional shares of common stock, (ii) 468,041 additional Series H Warrants, (iii) 468,041 additional Series I Warrants, and/or (iv) 468,041 additional Series J Warrants,

01 Other Events

Item 8.01 Other Events. On August 30, 2024, the Company issued a press release announcing that it had priced the Public Offering, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. On September 3, 2024, the Company issued a press release announcing the closing of the Public Offering and the partial exercise of the Overallotment Option, a copy of which is attached as Exhibit 99.2 to this Current Report and is incorporated herein by reference. At the close of business on the closing date of the Public Offering, the Company had 2,656,652 shares of common stock issued and outstanding, including 862,000 shares of common stock that were issued on the closing date of the Public Offering upon the exercise of Pre-Funded Warrants. At the close of business on September 5, 2024, the Company had 2,804,152 shares of common stock issued and outstanding, including an additional 147,500 shares of common stock that were issued after the closing date of the Public Offering upon the exercise of Pre-Funded Warrants. Information contained on or accessible through any website referenced in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is as inactive textual references only. 3

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement dated as of September 3, 2024, by and between Catheter Precision, Inc. and Ladenburg Thalmann & Co. Inc., as Representative of the Underwriters 4.1 Form of Series H Common Stock Purchase Warrant 4.2 Form of Series I Common Stock Purchase Warrant 4.3 Form of Series J Common Stock Purchase Warrant 4.4 Form of Pre-Funded Common Stock Purchase Warrant 4.5 Warrant Agency Agreement dated September 3, 2024, by and between Catheter Precision, Inc. and Equiniti Trust Company, LLC 99.1 Press release dated August 30, 2024 99.2 Press release dated September 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: September 6, 2024 /s/ Margrit Thomassen Margrit Thomassen Interim Chief Financial Officer and Secretary 5

View Full Filing

View this 8-K filing on SEC EDGAR